Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Genital Neoplasms, Female: later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Genital Neoplasms, Female: 1 US clinical trial tracked, none currently recruiting.

Genital Neoplasms, Female is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 1 of these trials.

Enrollment posture brief

Registry condition genital-neoplasms-female

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Genital Neoplasms, Femal (th…0%
Open-enrollment share among volume-matched conditions near Genital Neoplasms, Female

Genital Neoplasms, Female has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Genital Neoplasms, Female on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Genital Neoplasms, Female is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Genital Neoplasms, Female records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

liposomal doxorubicin Drug
1 trials
Gemcitabine Drug
1 trials

US sites by state

Facility locations filed on Genital Neoplasms, Female trials. A trial with sites in several states counts in each.

Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Genital Neoplasms, Female page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Genital Neoplasms, Female trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Eli Lilly and Company sponsors the most Genital Neoplasms, Female trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Genital Neoplasms, Female condition card totals 1 registered trials; most-linked intervention liposomal doxorubicin; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.